A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2
Authors:
Preprint
Abstract
As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus; whether through infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the ability to measure SARS-CoV-2 immunity, ideally with rapid turnaround and without the need for laboratory-based testing. Current rapid point-of-care (POC) tests measure antibodies (Ab) against the SARS-CoV-2 virus, however, these tests provide no information on whether the antibodies can neutralise virus infectivity and are potentially protective, especially against newly emerging variants of the virus. Neutralising Antibodies (NAb) are emerging as a strong correlate of protection, but most current NAb assays require many hours or days, samples of venous blood, and access to laboratory facilities, which is especially problematic in resource-limited settings. We have developed a lateral flow POC test that can measure levels of RBD-ACE2 neutralising antibodies from whole blood, with a result that can be determined by eye (semi-quantitative) or on a small instrument (quantitative), and results show high correlation with microneutralisation assays. This assay also provides a measure of total anti-RBD antibody, thereby providing evidence of exposure to SARS-CoV-2 or immunisation, regardless of whether NAb are present in the sample. By testing samples from immunised macaques, we demonstrate that this test is equally applicable for use with animal samples, and we show that this assay is readily adaptable to test for immunity to newly emerging SARS-CoV-2 variants. Lastly, using a cohort of vaccinated humans, we demonstrate that our whole-blood test correlates closely with microneutralisation assay data (R 2 =0.75, p<0.0001), and that fingerprick whole blood samples are sufficient for this test. Accordingly, the COVID-19 NAb-test™ device described here can provide a rapid readout of immunity to SARS-CoV-2 at the point of care.Keywords
All Related Versions
- Published version: EBioMedicine, 74, 103729.
This publication has 30 references indexed in Scilit:
- Structural Basis for RNA Replication by the SARS-CoV-2 PolymeraseCell, 2020
- Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence settingmedRxiv, 2020
- A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 bindingmedRxiv, 2020
- Isolation and rapid sharing of the 2019 novel coronavirus ( SARS ‐CoV‐2) from the first patient diagnosed with COVID ‐19 in AustraliaMedical Journal of Australia, 2020
- Potent human neutralizing antibodies elicited by SARS-CoV-2 infectionbioRxiv, 2020
- Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibodyEmerging Microbes & Infections, 2020
- Field Performance and Diagnostic Accuracy of a Low-Cost Instrument-Free Point-of-Care CD4 Test (Visitect CD4) Performed by Different Health Worker Cadres among Pregnant WomenJournal of Clinical Microbiology, 2019
- Transient expression of human antibodies in mammalian cellsNature Protocols, 2017
- Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunityProceedings of the National Academy of Sciences, 2004
- Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of MiceJournal of Virology, 2004